Internal Reference Number: FOI_8591
Date Request Received: 15/04/2025 00:00:00
Date Request Replied To: 09/05/2025 00:00:00
This response was sent via: By Email
Request Summary: new biologic and targeted medications - Gastroenterology
Request Category: Researcher
| Question Number 1: . How many patients were treated in March 2025 (or latest available month) by the gastroenterology department with the following biologic drugs? • Etrasimod • Filgotinib • Golimumab • Mirikizumab • Ozanimod • Risankizumab • Tofacitinib • Upadacitinib • Ustekinumab (Stelara) • Ustekinumab Biosimilar • Vedolizumab | |
| Answer To Question 1: Patients on treatment in April 2025: • Etrasimod 0 • Filgotinib <5 • Golimumab <5 • Mirikizumab 6 • Ozanimod 0 • Risankizumab 11 • Tofacitinib <5 • Upadacitinib 29 • Ustekinumab (Stelara) 8 • Ustekinumab Biosimilar 83 • Vedolizumab 60 | |
| Question Number 2: How many patients were treated in March 2025 (or latest available month) for Crohn's disease with the following biologic drugs? • Golimumab • Risankizumab • Upadacitinib • Ustekinumab (Stelara) • Ustekinumab Biosimilar • Vedolizumab | |
| Answer To Question 2: Patients treated in April 2025: • Golimumab <5 • Risankizumab 11 • Upadacitinib 16 • Ustekinumab (Stelara) 6 • Ustekinumab Biosimilar 71 • Vedolizumab 16 | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
